PRAC recommends new measures to avoid valproate exposure in pregnancy
New restrictions on use; pregnancy prevention programme to be put in place
The European Medicines Agency’s experts in medicines safety, the Pharmacovigilance Risk Assessment Committee (PRAC) are recommending new measures to avoid exposure of babies to valproate medicines in the womb. Babies exposed are at risk of malformations and developmental problems.
What are the main measures recommended by the PRAC?
- Where licensed for migraine or bipolar disorder:
- In pregnancy - valproate must not be used.
- In female patients from the time they become able to have children – valproate must not be used unless the conditions of a new pregnancy prevention programme (see below) are met.
- For epilepsy:
- In pregnancy - valproate must not be used. However it is recognised that for some women with epilepsy it may not be possible to stop valproate and they may have to continue treatment (with appropriate specialist care) in pregnancy.
- In female patients from the time they become able to have children – valproate must not be used unless the conditions of the new pregnancy prevention programme are met.
- The PRAC has also recommended that the outer packaging of all valproate medicines must include a visual warning about the risks in pregnancy. In addition to boxed text, this may include a symbol/pictogram, with the details to be adapted at national level.
- A patient reminder card will also be attached to the outer package for pharmacists to discuss with the patient each time the medicine is dispensed.
- Companies that market valproate should also provide updated educational materials in the form of guides for healthcare professionals and patients.
What are the main points of the new valproate pregnancy prevention programme?
- Assessing patients for the potential of becoming pregnant, and involving the patient in evaluating her individual circumstances and supporting informed decision making,
- pregnancy tests before starting and during treatment as needed,
- counselling patients about the risks of valproate treatment,
- explaining the need for effective contraception throughout treatment,
- carrying out reviews of treatment by a specialist at least annually,
- introduction of a new risk acknowledgement form that patients and prescribers will go through at each such review to confirm that appropriate advice has been given and understood.
Medicines containing valproate have been approved nationally in the EU to treat epilepsy, bipolar disorder and in some countries for prevention of migraine. They are known to pose a considerable risk of malformations and developmental problems in babies who are exposed to valproate in the womb. An earlier review had recommended measures aimed at better informing women about these risks in order to reduce use of the medicine during pregnancy, and not starting treatment unless other options were ineffective or could not be used because of side effects. The current review was launched because of concerns that these measures had not been sufficiently effective.
The PRAC examined the available evidence and consulted widely with healthcare professionals and with patients, including women and their children who have been affected by valproate use during pregnancy, through written submissions, expert meetings, meetings with stakeholders including healthcare professionals, patients organisations, patients and their families, and via a public hearing. The PRAC noted that women were still not always receiving the right information in a timely manner and that further measures were needed to help avoid use during pregnancy. However, it was also clear that for some women, such as those with particular forms of epilepsy, valproate is the only appropriate treatment and might be life-saving.
The PRAC therefore considered that the way the products are used should be changed. It recommended strengthening restrictions on their use and introducing new measures to require appropriate counselling and information for affected women.
The PRAC also recommended that the companies marketing these medicines carry out additional studies to further characterise the nature and extent of the risks posed by valproate and to monitor ongoing valproate use and the long-term effects from affected pregnancies.
Because valproate medicines are all licensed at national level, the PRACrecommendations will now be sent to Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), which will adopt a position.
In the meantime, women who have any concerns should consult their doctor. Women and girls who have been prescribed valproate should not stop taking their medicines without consulting their doctor as doing so could result in harm to themselves or to an unborn child.
More about the medicine
Valproate medicines are used to treat epilepsy and bipolar disorder. In some EU Member States they are also authorised to prevent migraine headaches.
The active ingredient in these medicines may be valproic acid, magnesium valproate, sodium valproate, valproate semisodium or valpromide.
Valproate medicines have been authorised via national procedures in all EU Member States and in Norway and Iceland. They are marketed under several brand names including: Absenor, Convival Chrono, Convulex, Delepsine, Depakin, Depakine, Depakote, Depamag, Depamide, Deprakine, Diplexil, Dipromal, Epilim, Episenta, Epival, Ergenyl, Espa-Valept, Hexaquin, Kentlim, Leptilan, Micropakine L.P., Orfiril, Petilin, Valepil, Valhel PR, Valpal, Valpro and Valprolek.
More about the procedure
The review of valproate medicines was initiated on 9 March 2017 at the request of the French medicines regulator ANSM, under Article 31 of Directive 2001/83/EC.
The review has been carried out by the Pharmacovigilance Risk Assessment Committee(PRAC), the Committee responsible for the evaluation of safety issues for human medicines, which has made a set of recommendations. The PRAC recommendations will now be sent to Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), which will adopt a position. The CMDh is responsible for ensuring harmonised safety standards for medicines authorised via national procedures across the EU.
 The CMDh is a medicines regulatory body representing the European Union (EU) Member States, Iceland, Liechtenstein and Norway.
|PRAC recommends new measures to avoid valproate exposure in pregnancy||(English only)||09/02/2018|
Latest News from
Stronger EU borders with a new standing corps of 10,000 border guards18/04/2019 15:25:00
TheEuropean Parliament hasadopted the ECs proposal to reinforce the European Border and Coast Guard Agency with a standing corps of 10,000 border guards by 2027.
European Parliament's vote on new rules to improve fairness & transparency of online platforms18/04/2019 13:37:00
The European Parliament has approved the new Regulation on platform-to-business trading practices that is aimed at establishing a fair, trusted and innovation-driven environment for businesses and traders when using online platforms.
WTO Boeing dispute: EU issues preliminary list of U.S. products considered for countermeasures18/04/2019 12:25:00
The EC has launched a public consultation on a preliminary list of products from the USA on which the EU may take countermeasures in the context of the ongoing Boeing dispute at the World Trade Organisation (WTO).
Registered substances mapped for regulatory action18/04/2019 09:25:00
The first report of the Integrated Regulatory Strategy presents a mapping of the universe of registered substances that are on the EU market. This information helps authorities to identify, plan and monitor the progress on identifying and regulating substances of concern.
The United States is Europe's main soya beans supplier with imports up by 121%17/04/2019 16:25:00
New figures released by the EC, show that imports of U.S. soya beans by the EU increased by 121% over the current market year (July 2018 to mid-April 2019), compared to the same period in the previous year.
EC updates the EU Air Safety List to maintain highest level of protection for passengers17/04/2019 15:37:00
The EC has updated the EU Air Safety List, the list of airlines that do not meet international safety standards, and are therefore subject to an operating ban or operational restrictions within the EU.
EC launches debate on more efficient decision-making in EU social policy17/04/2019 13:25:00
In his 2018 State of the Union speech, President Juncker announced a comprehensive review of all passerelle clauses provided for by the EU Treaties. As a result, three Communications have already been adopted: on common foreign and security policy (September 2018), on taxation (January 2019) and on energy and climate (April 2019). The Communication on the passerelle clauses in social policy is the fourth one.
EC welcomes adoption of new measures denying terrorists & criminals the means and space to act17/04/2019 12:37:00
The European Parliament has adopted 2 important Security Union legislative initiatives proposed by the EC on interoperability and explosive precursors.
ESMA publishes translations for Guidelines on CCP APC Margin Measures17/04/2019 09:25:00
The European Securities and Markets Authority (ESMA) recently (15 April 2019) issued the official translations of its Guidelines on EMIR Anti-Procyclicality Margin Measures for Central Counterparties.